Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518332 | 1.00 | HPGD (0.46) | HPGDCASP1HTTSMN1; SMN2KMT2A | |
| SCHEMBL518333 | 1.00 | HPGD (0.46) | HPGDCASP1HTTSMN1; SMN2KMT2A | |
| SCHEMBL10266945 | 0.89 | KMT2A (0.47) | HPGDCASP1HTTSMN1; SMN2KMT2A | |
| SCHEMBL518865 | 0.81 | KDM4E (0.45) | HPGDHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7790215 | 0.81 | KDM4E (0.45) | HPGDHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL518866 | 0.81 | KDM4E (0.45) | HPGDHTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL518936 | 0.79 | HTT (0.52) | HPGDCASP1HTTSMN1; SMN2KMT2A | |
| SCHEMBL14974481 | 0.75 | MAPT (0.44) | HPGDHTTSMN1; SMN2RAB9AGAA | |
| SCHEMBL14974480 | 0.75 | MAPT (0.44) | HPGDHTTSMN1; SMN2RAB9AGAA | |
| SCHEMBL13259472 | 0.75 | ALDH1A1 (0.48) | HPGDCASP1HTTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2393360-B1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8513251-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | HPGD 593/4885CASP1 2331/4885HTT 3986/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | HPGD 593/4885CASP1 2331/4885HTT 3986/4885 |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | HPGD 193/4885CASP1 2565/4885HTT 3885/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | HPGD 203/4885CASP1 2626/4885HTT 3917/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | HPGD 593/4885CASP1 2331/4885HTT 3986/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | HPGD 593/4885CASP1 2331/4885HTT 3986/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | HPGD 550/4885CASP1 2514/4885HTT 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.